OMISIRGE (Omidubicel-onlv)

Omisirge (omidubicel-onlv) is an ex-vivo expanded cell therapy derived from umbilical cord blood, engineered to enhance hematopoietic recovery following stem cell transplantation. Omisirge is manufactured using proprietary nicotinamide (NAM) technology, which modifies the stem cells to improve their functionality and speed up recovery. Ex-vivo expansion of cord blood derived hematopoietic progenitor cells (HPCs) in the presence of NAM leads to preservation of their stemness, supports bone marrow (BM) engraftment, and enables rapid neutrophil and multilineage immune recovery as demonstrated in clinical trials. <a id="